Advances in polymeric and non-polymeric nanocarriers for the magnified delivery of levofloxacin against bacterial infection
Source abstract
Abstract
Abstract This review examines the latest developments in nanoscopic antibiotic formulations used to treat infections caused by bacteria. A wide range of nanocarrier platforms are discussed, including polymer-based nanoparticles (NPs), lipid-based vesicles, mesoporous silica, and other inorganic materials. The antibiotic levofloxacin (LVF) is predominantly used as a model drug given its broad-spectrum activity. Studies in this regard have evaluated drug loading and encapsulation efficiency (EE) using analytical techniques such as FTIR, DLS, and TEM. In vitro release kinetics was characterized through dialysis and fluorescence-based assays. Zone of inhibition and viability studies provided insights into antibacterial efficacy. Some approaches incorporated stimuli-responsive polymers or targeting ligands to facilitate controlled or targeted drug release. Overall, the nanocarriers demonstrated potential for sustained antibiotic levels, reduced dosing, and improved treatment of biofilms and intracellular infections compared to free drug administration. The review offers a comprehensive analysis of this promising field with implications for combating antibiotic resistance.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Orthopedic Infections and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Doron S and Gorbach SL (2008) Bacterial infections: overview, in International Encyclopedia of Public Health, pp 273–28210.1016/B978-012373960-5.00596-7 ↗
2. Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3(1):16–2010.1021/nn900002m ↗
3. Suri SS, Fenniri H, Singh B (2007) Nanotechnology-based drug delivery systems. J Occup Med Toxicol 2:1–610.1186/1745-6673-2-16 ↗
4. Das SS et al (2020) Stimuli-responsive polymeric nanocarriers for drug delivery, imaging, and theragnosis. Polymers 12(6):139710.3390/polym12061397 ↗
5. Duro-Castano A, Talelli M, Rodríguez-Escalona G, Vicent MJSP (2019) and t. Applications, Smart polymeric nanocarriers for drug delivery, pp 439–479
6. Anwer MK et al (2021) Development of sustained release baricitinib loaded lipid-polymer hybrid nanoparticles with improved oral bioavailability. Molecules 27(1):16810.3390/molecules27010168 ↗
7. Mu H, Holm R (2018) Solid lipid nanocarriers in drug delivery: characterization and design. Expert Opin Drug Deliv 15(8):771–78510.1080/17425247.2018.1504018 ↗
8. Bharti C, Nagaich U, Pal AK, Gulati N (2015) Mesoporous silica nanoparticles in target drug delivery system: A review. Int J Pharma Investig 5(3):12410.4103/2230-973X.160844 ↗
9. Ghaemi A et al (2024) Targeted nano-delivery of flutamide with polymeric and lipid nanoparticles. Eur Polym J 213:113124. https://doi.org/10.1016/j.eurpolymj.2024.11312410.1016/j.eurpolymj.2024.113124 ↗
10. Khanizadeh A et al (2024) Advancing cancer therapy: unveiling the cutting-edge potential of carmustine nano carriers for targeted treatment. J Drug Deliv Sci Technol 99:105943. https://doi.org/10.1016/j.jddst.2024.10594310.1016/j.jddst.2024.105943 ↗
11. Pourmadadi M et al (2024) Polymeric nanoparticles as delivery vehicles for targeted delivery of chemotherapy drug fludarabine to treat hematological cancers. Inorg Chem Commun, 112819. https://doi.org/10.1016/j.inoche.2024.11281910.1016/j.inoche.2024.112819 ↗
12. Davis R, Bryson HM (1994) Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47:677–70010.2165/00003495-199447040-00008 ↗
13. Duffy LB, Crabb DM, Bing X, Waites KB (2003) Bactericidal activity of levofloxacin against Mycoplasma pneumoniae. J Antimicrob Chemother 52(3):527–52810.1093/jac/dkg365 ↗
14. Critchley I et al (2002) In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 8(4):214–22110.1046/j.1469-0691.2002.00392.x ↗
15. Croom KF, Goa KL (2003) Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 63:2769–280210.2165/00003495-200363240-00008 ↗
16. Wimer SM, Schoonover L, Garrison MW (1998) Levofloxacin: a therapeutic review. Clin Ther 20(6):1049–107010.1016/S0149-2918(98)80104-5 ↗
17. Norrby SR (1999) Levofloxacin. Expert Opin Pharma 1(1):109–11910.1517/14656566.1.1.109 ↗
18. LEVAQUIN (Levofloxacin) (2006) USPI proposed interactions with laboratory or diagnostic testing, January 2006. [Online]: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020634s039,020635s042,021721s006lbl.pdf
19. Guo W, Shi Y, Wang H, Yang H, Zhang GJWER (2010) Sonochemical decomposition of levofloxacin in aqueous solution. Water Environ Res 82(8):696–70010.2175/106143010X12609736966801 ↗
20. Smith L, Angarone MPJUC (2015) Sexually transmitted infections. Urologic Clin 42(4):507–518
21. Aljamali NM, Al-zubaidy ZH, Enad AHJPN (2021) Bacterial infection and common bacterial diseases: a review. Pharm. Nanotechnol 3:13–23
22. Sell J, Dolan B (2018) Common gastrointestinal infections. Primary Care: Clinics in Office Practice 45(3):519–53210.1016/j.pop.2018.05.008 ↗
23. Czyrski A, Kondys K (2016) Levofloxacin–its practical application in the treatment and pharmacokinetics. Farmacja Współczesna 9:1–7
24. Ong PY, Leung DY (2016) Bacterial and viral infections in atopic dermatitis: a comprehensive review. Clin Rev Allerg Immunol 51:329–33710.1007/s12016-016-8548-5 ↗
25. Keam SJ (2019) Pretomanid: first approval. Drugs 79(16):1797–180310.1007/s40265-019-01207-9 ↗
26. Veve MP, Wagner JL (2018) Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharm: J Human Pharmacol Drug Ther 38(9):935–946
27. Zhanel GG et al (2019) Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs 79:271–28910.1007/s40265-019-1055-2 ↗
28. Wirth DDJT (1993) Carboxylic sulfonic mixed anhydrides: general utility and application to the synthesis of ceftazidime. Tetrahedron 49(8):1535–154010.1016/S0040-4020(01)80340-9 ↗
29. Richards DM, Brogden RN (1985) Ceftazidime: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 29(2):105–16110.2165/00003495-198529020-00002 ↗
30. Ball M et al (2016) Development of a manufacturing route to avibactam, a β-lactamase inhibitor. Organ Process Res Dev 20(10):1799–180510.1021/acs.oprd.6b00268 ↗
31. Lomovskaya O et al (2017) Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrobial Agents Chemother 61(11):10–12810.1128/AAC.01443-17 ↗
32. Honeyman L et al (2015) Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrobial Agent Chemother 59(11):7044–705310.1128/AAC.01536-15 ↗
33. Candel FJ, Peñuelas M (2017) Delafloxacin: design, development and potential place in therapy. Drug Des, Dev Ther 20:881–9110.2147/DDDT.S106071 ↗
34. Vila Estapé J et al (2019) Ozenoxacin: a review of preclinical and clinical efficacy. Expert Rev Anti-infect Ther 17(3):159–6810.1080/14787210.2019.1573671 ↗
35. Calvert MB, Furkert DP, Cooper CB, Brimble MA (2020) Synthetic approaches towards bedaquiline and its derivatives. Bioorgan Med Chem Lett 30(12):12717210.1016/j.bmcl.2020.127172 ↗
36. Hussar DA (2019) New drugs 2019, part 4. Nursing2023 49(11):34–4310.1097/01.NURSE.0000585892.82614.f4 ↗
37. Prabhu VS et al (2018) Cost-effectiveness of bezlotoxumab compared with placebo for the prevention of recurrent Clostridium difficile infection. Clin Infect Dis 66(3):355–36210.1093/cid/cix809 ↗
38. Hou AW, Morrill AM (2017) Obiltoxaximab: adding to the treatment arsenal for Bacillus anthracis infection. Annal Pharmacother 51(10):908–1310.1177/1060028017713029 ↗
39. Cao D et al (2021) Levofloxacin versus ciprofloxacin in the treatment of urinary tract infections: Evidence-based analysis. Front Pharmacol 12:65809510.3389/fphar.2021.658095 ↗
40. Bush LM, Chaparro-Rojas F, Okeh V, Etienne J (2011) Cumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections: critical appraisal and role in therapy. Infect Drug Resist 18:177–8910.2147/IDR.S15610 ↗
41. Asseray N et al (2016) Levofloxacin at the usual dosage to treat bone and joint infections: a cohort analysis. Int J Antimicrob Agents 47(6):478–48110.1016/j.ijantimicag.2016.03.003 ↗
42. Minehart HW, Chalker AF (2001) In vitro activity of gemifloxacin against Helicobacter pylori. J Antimicrob Chemother 47(3):360–110.1093/jac/47.3.360 ↗
43. Hooper DC, Jacoby GA (2015) Mechanisms of drug resistance: quinolone resistance. Annal New York Acad Sci 1354(1):12–3110.1111/nyas.12830 ↗
44. Izadi E et al (2019) Levofloxacin: insights into antibiotic resistance and product quality. Front Pharmacol 10:88110.3389/fphar.2019.00881 ↗
45. Brooks BD, Brooks AE (2014) Therapeutic strategies to combat antibiotic resistance. Adv Drug Deliv Rev 78:14–2710.1016/j.addr.2014.10.027 ↗
46. Guilhelmelli F, Vilela N, Albuquerque P, Derengowski LD, Silva-Pereira I, Kyaw CM (2013) Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front Microbiol 4:35310.3389/fmicb.2013.00353 ↗
47. Burrowes B, Harper DR, Anderson J, McConville M, Enright MC (2011) Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev Anti-Infect Ther 9(9):775–8510.1586/eri.11.90 ↗
48. Worthington RJ, Melander C (2013) Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol 31(3):177–8410.1016/j.tibtech.2012.12.006 ↗
49. Altemimi AB et al (2024) Application of nanoparticles in human nutrition: a review. Nutrients 16(5):63610.3390/nu16050636 ↗
50. Khandare J, Minko T (2006) Polymer–drug conjugates: progress in polymeric prodrugs. Progress Polym Sci 31(4):359–9710.1016/j.progpolymsci.2005.09.004 ↗
51. Hoste K, De Winne K, Schacht E (2004) Polymeric prodrugs. Int J Pharm 277(1–2):119–3110.1016/j.ijpharm.2003.07.016 ↗
52. Ono S, Imai R, Ida Y, Shibata D, Komiya T, Matsumura HJB (2015) Increased wound pH as an indicator of local wound infection in second degree burns. Burns 41(4):820–82410.1016/j.burns.2014.10.023 ↗
53. Fierheller M, Sibbald RG (2010) A clinical investigation into the relationship between increased periwound skin temperature and local wound infection in patients with chronic leg ulcers. Adv Skin Wound Care 23(8):369–7910.1097/01.ASW.0000383197.28192.98 ↗
54. Cheow WS, Hadinoto K (2011) Factors affecting drug encapsulation and stability of lipid–polymer hybrid nanoparticles. Colloid Surf B: Biointerf 85(2):214–2010.1016/j.colsurfb.2011.02.033 ↗
55. Shah SR et al (2020) Pharmacokinetics and in vivo distribution of optimized PLGA nanoparticles for pulmonary delivery of levofloxacin. J Pharm Pharmacol 72(8):1026–103710.1111/jphp.13275 ↗
56. Ali I et al (2020) Progress in polymeric nano-medicines for theranostic cancer treatment. Polymers 12:59810.3390/polym12030598 ↗
57. Jalvandi J et al (2017) Polyvinyl alcohol composite nanofibres containing conjugated levofloxacin-chitosan for controlled drug release. Mater Sci Eng 73:440–44610.1016/j.msec.2016.12.112 ↗
58. Corduas F et al (2021) Melt-extrusion 3D printing of resorbable levofloxacin-loaded meshes: emerging strategy for urogynaecological applications. Mater Sci Eng: C 131:11252310.1016/j.msec.2021.112523 ↗
59. Agha OA, Girgis GN, El-Sokkary MM, Soliman OA (2023) Spanlastic-laden in situ gel as a promising approach for ocular delivery of levofloxacin: in-vitro characterization, microbiological assessment, corneal permeability and in-vivo study. Int J Pharm: X 6:100201
60. Kırımlıoğlu GY, Yazan YJEIJST (2016) Formulation and in vitro characterization of polymeric nanoparticles designed for oral delivery of levofloxacin hemihydrate. Eu Int J Sci Tech 6:655–658
61. Imam SS, Bukhari SN, Ahmad J, Ali A (2018) Formulation and optimization of levofloxacin loaded chitosan nanoparticle for ocular delivery: In-vitro characterization, ocular tolerance and antibacterial activity. Int J Biol Macromol 108:650–910.1016/j.ijbiomac.2017.11.170 ↗
62. Cheow WS, Hadinoto K (2010) Enhancing encapsulation efficiency of highly water-soluble antibiotic in poly (lactic-co-glycolic acid) nanoparticles: modifications of standard nanoparticle preparation methods. Colloids Surf, A 370(1–3):79–8610.1016/j.colsurfa.2010.08.050 ↗
63. Derbali RM et al (2019) Tailored nanocarriers for the pulmonary delivery of levofloxacin against Pseudomonas aeruginosa: a comparative study. Mol Pharm 16(5):1906–191610.1021/acs.molpharmaceut.8b01256 ↗
64. Gevariya HB, Gami S, Patel N (2011) Formulation and characterization of levofloxacin-loaded biodegradable nanoparticles. Asian J Pharm 5(2):114–11910.4103/0973-8398.84552 ↗
65. Siafaka P, Okur ME, Ayla Ş, Er S, Cağlar EŞ, Okur NÜ (2019) Design and characterization of nanocarriers loaded with levofloxacin for enhanced antimicrobial activity; physicochemical properties, in vitro release and oral acute toxicity. Braz J Pharm Sci 55:e1829510.1590/s2175-97902019000118295 ↗
66. Alves DA et al (2016) Preparation of thermosensitive gel for controlled release of levofloxacin and their application in the treatment of multidrug-resistant bacteria. Biomed Res Int 2016(1):9702129
67. Gaspar MC et al (2015) Optimization of levofloxacin-loaded crosslinked chitosan microspheres for inhaled aerosol therapy. Eur J Pharm Biopharm 96:65–7510.1016/j.ejpb.2015.07.010 ↗
68. Gupta H, Aqil M, Khar R, Ali A, Bhatnagar A, Mittal G (2011) Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J Drug Target 19(6):409–41710.3109/1061186X.2010.504268 ↗
69. Fatahi Y et al (2021) Levofloxacin-halloysite nanohybrid-loaded fibers based on poly (ethylene oxide) and sodium alginate: fabrication, characterization, and antibacterial property. J Drug Deliv Sci Technol 64:10259810.1016/j.jddst.2021.102598 ↗
70. Kumar G, Sharma S, Shafiq N, Khuller GK, Malhotra S (2012) Optimization, in vitro–in vivo evaluation, and short-term tolerability of novel levofloxacin-loaded PLGA nanoparticle formulation. J Pharm Sci 101(6):2165–217610.1002/jps.23087 ↗
71. Kumar A, Sharma S, Srivastava A, Kumar R (2017) Synthesis of xanthan gum graft copolymer and its application for controlled release of highly water soluble levofloxacin drug in aqueous medium. Carbohyd Polym 171:211–21910.1016/j.carbpol.2017.05.010 ↗
72. Li G et al (2021) Levofloxacin-loaded nanosonosensitizer as a highly efficient therapy for bacillus Calmette-Guerin infections based on bacteria-specific labeling and sonotheranostic strategy. Int J Nanomed 24:6553–7310.2147/IJN.S321631 ↗
73. Wang Z et al (2021) Novel contact lenses embedded with drug-loaded zwitterionic nanogels for extended ophthalmic drug delivery. Nanomaterials 11(9):232810.3390/nano11092328 ↗
74. İmamoğlu S, Devrim Gökberk B, Eryilmaz M, Bozkir A (2022) Effect of surfactant types and concentrations on levofloxacin-loaded PLGA microparticles for pulmonary delivery-An in vitro study. J Res Pharm 26(5):1156 –117610.29228/jrp.210 ↗
75. López-López M et al (2019) Optimized preparation of levofloxacin loaded polymeric nanoparticles. Pharmaceutics 11(2):5710.3390/pharmaceutics11020057 ↗
76. De Gaetano F et al (2021) Development of chitosan/cyclodextrin nanospheres for levofloxacin ocular delivery. Pharmaceutics 13(8):129310.3390/pharmaceutics13081293 ↗
77. Puppi D, Piras AM, Pirosa A, Sandreschi S, Chiellini F (2016) Levofloxacin-loaded star poly (ε-caprolactone) scaffolds by additive manufacturing. J Mater Sci - Mater Med 27:1–1110.1007/s10856-015-5658-1 ↗
78. the effect of antibiotic release profile (2010) W. S. Cheow, M. W. Chang, K. Hadinoto, Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells. Pharm Res 27:1597–160910.1007/s11095-010-0142-6 ↗
79. Xie S et al (2020) A synergistic bactericidal effect of low-frequency and low-intensity ultrasound combined with levofloxacin-loaded PLGA nanoparticles on M. smegmatis in macrophages. J Nanobiotechnol 18:1–1510.1186/s12951-020-00658-7 ↗
80. Maharini I, Nugroho AK, Martien R, Supanji S (2023) D-optimal mixture design application to optimize formula of chitosan-alginate nanoparticle loaded with levofloxacin hemihydrate for ocular delivery. Available at SSRN: https://ssrn.com/abstract=449274110.2139/ssrn.4492741 ↗
81. Agnoletti M (2020) Antibiotic-loaded polymeric microspheres for passive lung targeting after intravenous administration (T). University of British Columbia. Retrieved from https://open.library.ubc.ca/collections/ubctheses/24/items/1.0392856
82. Zhang L-P, Tan X-X, Huang Y-P, Liu Z-S (2018) Floating liquid crystalline molecularly imprinted polymer coated carbon nanotubes for levofloxacin delivery. Eur J Pharm Biopharm 127:150–15810.1016/j.ejpb.2018.02.012 ↗
83. Tan RYH, Lee CS, Pichika MR, Cheng SF, Lam KY (2022) PH responsive polyurethane for the advancement of biomedical and drug delivery. Polymers 14(9):167210.3390/polym14091672 ↗
84. Imran M et al (2016) Sugar-based novel niosomal nanocarrier system for enhanced oral bioavailability of levofloxacin. Drug Delivery 23(9):3653–366410.1080/10717544.2016.1214991 ↗
85. Bhalerao H, Koteshwara K, Chandran S (2019) Levofloxacin hemihydrate in situ gelling ophthalmic solution: formulation optimization and in vitro and in vivo evaluation. AAPS PharmSciTech 20:1–1210.1208/s12249-019-1489-6 ↗
86. Hassani M, Tahghighi A, Rohani M, Hekmati M, Ahmadian M, Ahmadvand H (2022) Robust antibacterial activity of functionalized carbon nanotube-levofloxacine conjugate based on in vitro and in vivo studies. Sci Rep 12(1):1006410.1038/s41598-022-14206-w ↗
87. Abdelbar MF, Shams RS, Morsy OM, Hady MA, Shoueir K, Abdelmonem R (2020) Highly ordered functionalized mesoporous silicate nanoparticles reinforced poly (lactic acid) gatekeeper surface for infection treatment. Int J Biol Macromol 156:858–86810.1016/j.ijbiomac.2020.04.119 ↗
88. Shin B et al (2018) Thermoresponsive drug controlled release from chitosan-based hydrogel embedded with poly (N-isopropylacrylamide) nanogels. J Polym Sci, Part A: Polym Chem 56(17):1907–191410.1002/pola.29073 ↗
89. Vasani RB, Szili EJ, Rajeev G, Voelcker NH (2017) On-demand antimicrobial treatment with antibiotic-loaded porous silicon capped with a pH-responsive dual plasma polymer barrier. Chem-An Asian J 12(13):1605–1410.1002/asia.201700427 ↗
90. Müller S, Cavallaro A, Vasilev K, Voelcker NH, Schönherr H (2016) Temperature-controlled antimicrobial release from poly (diethylene glycol methylether methacrylate)-functionalized bottleneck-structured porous silicon for the inhibition of bacterial growtH. Macromol Chem Phys 217(20):2243–225110.1002/macp.201600099 ↗
91. Loh JS et al (2021) Do lipid-based nanoparticles hold promise for advancing the clinical translation of anticancer alkaloids? Cancers 13(21):534610.3390/cancers13215346 ↗
92. Wang Y, Kho K, Cheow WS, Hadinoto K (2012) A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid–polymer hybrid nanoparticles. Int J Pharm 424(1–2):98–10610.1016/j.ijpharm.2011.12.045 ↗
93. Islan GA, Tornello PC, Abraham GA, Duran N, Castro GR (2016) Smart lipid nanoparticles containing levofloxacin and DNase for lung delivery Design and characterization. Colloid Surf B: Biointerf 143:168–17610.1016/j.colsurfb.2016.03.040 ↗
94. Hady MA, Sayed OM, Akl MA (2020) Brain uptake and accumulation of new levofloxacin-doxycycline combination through the use of solid lipid nanoparticles: formulation; optimization and in-vivo evaluation. Colloids Surf, B 193:11107610.1016/j.colsurfb.2020.111076 ↗
95. Beraldo-Araújo VL et al (2022) Levofloxacin in nanostructured lipid carriers: preformulation and critical process parameters for a highly incorporated formulation. Int J Pharm 626:12219310.1016/j.ijpharm.2022.122193 ↗
96. Islan GA et al (2021) Effect of α-tocopherol on the physicochemical, antioxidant and antibacterial properties of levofloxacin loaded hybrid lipid nanocarriers. New J Chem 45(2):1029–104210.1039/D0NJ03781H ↗
97. Cicuendez M, Izquierdo-Barba I, Portolés MT, Vallet-Regí M (2013) Biocompatibility and levofloxacin delivery of mesoporous materials. Eur J Pharm Biopharm 84(1):115–12410.1016/j.ejpb.2012.11.029 ↗
98. Bayón B, Bucalá V, Castro GR (2016) Development of antimicrobial hybrid mesoporous silver phosphate–pectin microspheres for control release of levofloxacin. Microporous Mesoporous Mater 226:71–7810.1016/j.micromeso.2015.12.041 ↗
99. Jalvandi J, White M, Truong YB, Gao Y, Padhye R, Kyratzis IL (2015) Release and antimicrobial activity of levofloxacin from composite mats of poly (ɛ-caprolactone) and mesoporous silica nanoparticles fabricated by core–shell electrospinning. J Mater Sci 50:7967–797410.1007/s10853-015-9361-x ↗
100. Wang Q et al (2017) Levofloxacin loaded mesoporous silica microspheres/nano-hydroxyapatite/polyurethane composite scaffold for the treatment of chronic osteomyelitis with bone defects. Sci Rep 7(1):4180810.1038/srep41808 ↗